ClinicalTrials.gg
CompletedNCT02358044Updated Oct 3, 2018Results posted

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

A Phase 3 interventional study of Sofosbuvir and PegIntron in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
17th of 94
257 · median 75
Started
2015
with 13 others
Phase 3
30 of 94
none open now
Registered
37th of 94
by date

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 17th largest by enrollment, is one of 14 that started in 2015, is one of 30 in phase 3, and was the 37th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

This is a study comparing grazoprevir (MK-5172) plus elbasvir (MK-8742) treatment with sofosbuvir (SOF) plus Pegylated Interferon plus Ribavirin (RBV) [PR] treatment in treatment-naïve and prior PR treatment failure participants with chronic Hepatitis C Virus (HCV) genotype (GT)1, GT4, or GT6 infection. The primary objectives are to compare efficacy (assessed by the percentage of participants achieving sustained virologic response 12 weeks after ending study treatment [SVR12]) and safety between the grazoprevir plus elbasvir treatment arm and the SOF plus PR treatment arm. The primary hypothesis is that the percentage of participants achieving SVR12 in the grazoprevir plus elbasvir treatment arm is non-inferior to that in the SOF plus PR treatment arm.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weigh ≥40 kg and ≤125 kg
  • documented chronic GT1, GT4, or GT6 infection
  • cirrhosis/absence of cirrhosis defined by liver , Fibroscan, or FibroSure®
  • either treatment naïve or PR Null Responder, PR Partial Responder, or PR Prior Relapser
  • participant and partner both agree to use at least use at least 2 effective methods of from at least 2 weeks prior to Day 1 and continue until up to 6 months after last dose of study drug, or longer if dictated by local regulations

Exclusion criteria

Exclusion Criteria:

  • has evidence of decompensated liver disease
  • is coinfected with virus (e.g. hepatitis B surface antigen positive) or
  • history of ≤5 years prior to signing , or is under evaluation for other active or suspected malignancy
  • has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • has any of the following conditions: immunologically-mediated disease, organ transplants other than cornea and hair, poor venous access that precludes routine peripheral blood sampling, history of gastric surgery or malabsorption disorders, or any medical condition requiring, or likely to require, chronic systemic administration of during the course of the trial, history of chronic hepatitis not caused by
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Grazoprevir + Elbasvir

    Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.

    Drug: Sofosbuvir · Biological: PegIntron · Drug: Ribavirin

  • Active comparator
    SOF + PR

    Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.

    Drug: Grazoprevir/Elbasvir (100 mg/50 mg) FDC

Interventions

  • 400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.

  • BiologicalPegIntron

    PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.

  • Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.

  • DrugGrazoprevir/Elbasvir (100 mg/50 mg) FDC

    Drug pages: Grazoprevir · Elbasvir

    Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)

    Hepatitis C Virus ribonucleic acid (HCV-RNA) levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR12 was defined as HCV RNA below the lower limit of quantification (\<LLOQ) at 12 weeks after the end of all study therapy. The primary efficacy hypothesis for this study was that the percentage of participants achieving SVR12 in the grazoprevir plus elbasvir arm was non-inferior to the percentage in the SOF plus PR arm. A secondary statistical analysis was performed to determine whether the percentage of participants achieving SVR12 in the grazoprevir plus elbasvir arm was superior to the percentage in the SOF plus PR arm.

    Time frame: 12 weeks after end of all therapy (Study Week 24)

  2. Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The percentage of participants who experienced at least one AE was reported for each treatment arm.

    Time frame: Treatment + First 14 days of follow-up (Up to Week 14)

  3. Percentage of Participants Discontinuing Study Treatment Due to an AE

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The percentage of participants who discontinued study treatment due to an AE was reported for each treatment arm. Participants that discontinued study drug treatment due to an AE may have still continued on trial.

    Time frame: Up to Week 12

Secondary outcomes

  1. Percentage of Participants Experiencing at Least One Tier 1 Safety Event (Key Safety Parameter) During the Treatment Period and First 14 Follow-up Days

    Tier 1 safety events were pre-specified by the protocol to evaluate safety and test the safety superiority hypothesis. Tier 1 safety events were chosen to assess broad tolerability, hematological side effects and liver-related laboratory abnormalities. For this study, Tier 1 safety events included: any serious drug-related AE, any drug-related AE leading to permanent discontinuation (DC) of all study drugs, neutrophil count \<0.75 x 10\^9/L, hemoglobin \<10 g/dL, severe depression, hepatic events of clinical interest (defined by abnormal increases in alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or alkaline phosphatase \[ALP\]), or events meeting stopping rule criteria for DC from trial (due to abnormal increases of ALT, AST, or ALP with/without pre-specified related AEs). The percentage of participants who experienced each individual event that was defined as a Tier 1 safety event during the study treatment period was reported for each treatment arm.

    Time frame: Treatment + First 14 days of follow-up (Up to Week 14)

  2. Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)

    HCV-RNA levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR24 was defined as HCV RNA \<LLOQ at 24 weeks after the end of all study therapy.

    Time frame: 24 weeks after end of all therapy (Study Week 36)

  3. Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)

    HCV-RNA levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR4 was defined as HCV RNA \<LLOQ at 4 weeks after the end of all study therapy.

    Time frame: 4 weeks after end of all therapy (Study Week 16)

07

Results

Posted Jan 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneGrazoprevir + ElbasvirSOF + PR
Started129128
Treated129126
Completed127121
Not completed27
Withdrew: Adverse event01
Withdrew: Lost to follow-up21
Withdrew: Physician decision01
Withdrew: Withdrawal by subject04

Outcome measures

PrimaryPrimary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)

Hepatitis C Virus ribonucleic acid (HCV-RNA) levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR12 was defined as HCV RNA below the lower limit of quantification (\<LLOQ) at 12 weeks after the end of all study therapy. The primary efficacy hypothesis for this study was that the percentage of participants achieving SVR12 in the grazoprevir plus elbasvir arm was non-inferior to the percentage in the SOF plus PR arm. A secondary statistical analysis was performed to determine whether the percentage of participants achieving SVR12 in the grazoprevir plus elbasvir arm was superior to the percentage in the SOF plus PR arm.

Time frame:
12 weeks after end of all therapy (Study Week 24)
Reported as:
Number · percentage of participants
Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)99.290.5
Statistical analysis
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = <0.001 · Adjusted difference in percentage: 8.8 · 95% CI 3.6 to 15.3
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = 0.001 · Adjusted difference in percentage: 8.8 · 95% CI 3.6 to 15.3The lower bound of 95% CIs was compared to zero to evaluate superiority. The M=F approach was used to handle missing values.
PrimaryPercentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The percentage of participants who experienced at least one AE was reported for each treatment arm.

Time frame:
Treatment + First 14 days of follow-up (Up to Week 14)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days51.993.7
Statistical analysis
  • Grazoprevir + Elbasvir vs SOF + PR · Difference in percentage: -41.7 · 95% CI -51.1 to -31.9
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The percentage of participants who discontinued study treatment due to an AE was reported for each treatment arm. Participants that discontinued study drug treatment due to an AE may have still continued on trial.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Discontinuing Study Treatment Due to an AE
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Percentage of Participants Discontinuing Study Treatment Due to an AE0.80.8
SecondaryPercentage of Participants Experiencing at Least One Tier 1 Safety Event (Key Safety Parameter) During the Treatment Period and First 14 Follow-up Days

Tier 1 safety events were pre-specified by the protocol to evaluate safety and test the safety superiority hypothesis. Tier 1 safety events were chosen to assess broad tolerability, hematological side effects and liver-related laboratory abnormalities. For this study, Tier 1 safety events included: any serious drug-related AE, any drug-related AE leading to permanent discontinuation (DC) of all study drugs, neutrophil count \<0.75 x 10\^9/L, hemoglobin \<10 g/dL, severe depression, hepatic events of clinical interest (defined by abnormal increases in alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or alkaline phosphatase \[ALP\]), or events meeting stopping rule criteria for DC from trial (due to abnormal increases of ALT, AST, or ALP with/without pre-specified related AEs). The percentage of participants who experienced each individual event that was defined as a Tier 1 safety event during the study treatment period was reported for each treatment arm.

Time frame:
Treatment + First 14 days of follow-up (Up to Week 14)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Tier 1 Safety Event (Key Safety Parameter) During the Treatment Period and First 14 Follow-up Days
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Total Tier 1 AEs0.827.8
Tier 1 AE: Serious drug-related AE0.02.4
Tier 1 AE: DC due to drug-related AE0.00.8
Tier 1 AE: Neutrophil count <0.75 x 10^9/L0.012.7
Tier 1 AE: Hemoglobin <10 g/dL0.814.3
Tier 1 AE: Severe depression0.00.0
Tier 1 AE: Hepatic event of clinical interest0.00.0
Tier 1 AE: Trial DC due to stopping rule0.00.0
Statistical analysis
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = <0.001 (% of participants with ≥1 Tier 1 event = total number participants with ≥1 Tier 1 event ÷ total number ASaT participants within each treatment arm. M\&N method used to calculate a 2-sided 95% CI for the treatment difference and corresponding p-value.) · Difference in percentage: -27.0 · 95% CI -35.5 to -19.6
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = 0.078 (% of participants with ≥1 Tier 1 event = total number participants with ≥1 Tier 1 event ÷ total number ASaT participants within each treatment arm. M\&N method used to calculate a 2-sided 95% CI for the treatment difference and corresponding p-value.) · Difference in percentage: -2.4 · 95% CI -6.8 to 0.6
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = 0.312 (% of participants with ≥1 Tier 1 event = total number participants with ≥1 Tier 1 event ÷ total number ASaT participants within each treatment arm. M\&N method used to calculate a 2-sided 95% CI for the treatment difference and corresponding p-value.) · Difference in percentage: -0.8 · 95% CI -4.4 to 2.1
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = <0.001 (% of participants with ≥1 Tier 1 event = total number participants with ≥1 Tier 1 event ÷ total number ASaT participants within each treatment arm. M\&N method used to calculate a 2-sided 95% CI for the treatment difference and corresponding p-value.) · Difference in percentage: -12.7 · 95% CI -19.7 to -8.0
  • Grazoprevir + Elbasvir vs SOF + PR · Miettinen & Nurminen Method · p = <0.001 (% of participants with ≥1 Tier 1 event = total number participants with ≥1 Tier 1 event ÷ total number ASaT participants within each treatment arm. M\&N method used to calculate a 2-sided 95% CI for the treatment difference and corresponding p-value.) · Difference in percentage: -13.5 · 95% CI -20.8 to -7.9
SecondaryPercentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)

HCV-RNA levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR24 was defined as HCV RNA \<LLOQ at 24 weeks after the end of all study therapy.

Time frame:
24 weeks after end of all therapy (Study Week 36)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)98.489.7
Statistical analysis
  • Grazoprevir + Elbasvir vs SOF + PR · Adjusted difference in percentage: 8.8 · 95% CI 3.3 to 15.7
SecondaryPercentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)

HCV-RNA levels in plasma were measured using the Roche COBAS®AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 on blood samples drawn from each participant. SVR4 was defined as HCV RNA \<LLOQ at 4 weeks after the end of all study therapy.

Time frame:
4 weeks after end of all therapy (Study Week 16)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)
percentage of participantsGrazoprevir + ElbasvirSOF + PR
Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)99.2 (95.8 to 100.0)92.1 (85.9 to 96.1)

Adverse events

Collected over Up to Follow-up Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Grazoprevir + Elbasvir—1/129 (0.8%)44/129 (34.1%)
SOF + PR—6/126 (4.8%)114/126 (90.5%)
Most frequent serious events
Most frequent serious events
EventGrazoprevir + ElbasvirSOF + PR
AnaemiaBlood and lymphatic system disorders0/1291/126
Angina pectorisCardiac disorders0/1291/126
ProctitisGastrointestinal disorders0/1291/126
InfectionInfections and infestations0/1291/126
InfluenzaInfections and infestations0/1291/126
Proctitis infectiousInfections and infestations0/1291/126
ArthritisMusculoskeletal and connective tissue disorders0/1291/126
Cerebrovascular accidentNervous system disorders0/1291/126
Drug dependencePsychiatric disorders0/1291/126
Tooth abscessInfections and infestations1/1290/126
Most frequent other events
Showing 10 of 21
Most frequent other events
EventGrazoprevir + ElbasvirSOF + PR
PyrexiaGeneral disorders2/12968/126
HeadacheNervous system disorders17/12950/126
FatigueGeneral disorders9/12932/126
AstheniaGeneral disorders8/12930/126
Influenza like illnessGeneral disorders1/12923/126
ChillsGeneral disorders2/12921/126
MyalgiaMusculoskeletal and connective tissue disorders4/12919/126
AlopeciaSkin and subcutaneous tissue disorders1/12918/126
Decreased appetiteMetabolism and nutrition disorders1/12916/126
AnaemiaBlood and lymphatic system disorders1/12915/126

Baseline characteristics

Full Analysis Set (FAS); all randomized participants who receive at least one dose of study treatment. Two participants in the SOF + PR arm withdrew from study prior to treatment and were excluded from analysis.

Age, Continuous
Age, Continuous(years)Grazoprevir + ElbasvirSOF + PRTotal
Mean47.6 ± 12.448.2 ± 12.447.9 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Grazoprevir + ElbasvirSOF + PRTotal
Female7464138
Male5562117
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Platt HL. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. J Hepatol. 2016 Dec;65(6):1112-1119. doi: 10.1016/j.jhep.2016.07.050. Epub 2016 Aug 16. PubMed 27542322 ↗
  • Ng X, Nwankwo C, Arduino JM, Corman S, Lasch KE, Lustrino JM, Patel S, Platt HL, Qiu J, Sperl J. Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. Patient Prefer Adherence. 2018 Dec 11;12:2631-2638. doi: 10.2147/PPA.S172732. eCollection 2018. PubMed 30587935 ↗
  • Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018 Sep;38(9):1583-1591. doi: 10.1111/liv.13727. Epub 2018 Mar 31. PubMed 29461687 ↗
  • Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct. PubMed 29404492 ↗
  • Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018 May;53(5):679-688. doi: 10.1007/s00535-018-1429-3. Epub 2018 Jan 17. PubMed 29344726 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Nov 2015, 8 months.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2015
First posted
Feb 6, 2015
StartActual
Feb 27, 2015
Primary completionActual
Nov 26, 2015
CompletionActual
Feb 16, 2016
Results first posted
Jan 11, 2017
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02358044
Responsible party
Sponsor
First posted
Feb 6, 2015
Start date
Feb 27, 2015
Primary completion
Nov 26, 2015
Completion
Feb 16, 2016
Results posted
Jan 11, 2017
Last update
Oct 3, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion